A 2022 health-economics analysis in Circulation found that evolocumab was cost-effective at a threshold of $150,000 per quality-adjusted life year (QALY) when applied to patients with established ASCVD and baseline LDL-C 70 mg/dL, particularly those with a prior MI under age 65
Zhou Q, Chen B, Wang X, Wu L, Yang Y, Cheng X, Hu Z, Cai X, Yang J, Sun X, Lu W, Yan H, Chen J, Ye J, Shen J, Cao P
The company has faced challenges from supply shortages and increased competition, yet demand for Wegovy remains strong
In the fasted state, when glucose levels drop, glucagon is secreted by pancreatic -cells to trigger the release of stored glucose from the liver to maintain normal blood glucose levels
This is the single fastest way to determine real care